Use of Estriol at Distal Third of Vagina Improving Coital Pain in Post-menopause Women
NCT ID: NCT03116022
Last Updated: 2024-10-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
125 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-06-01
Study Completion Date
2024-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypoestrogenism leads to vaginal wall changes resulting in diminished vaginal lubrication and, consequently, causing pain during intercourse. Topical estrogen therapy (THT) may control this complaint. However, there are limitations on its use, especially in patients with breast cancer and diagnosed endometrial cancer. This randomized clinical trial aims to assess the impact of local estriol therapy in postmenopausal women complaining of coital pain and to assess serum concentrations of estriol in these women after estriol use. One-hundred-thirty-two women aged between 40 and 65 years will be randomized into three groups: Women using estriol 1 mg / 1g at the proximal third of vagina every other night - estriol proximal group (PEG), women in using estriol 1 mg / 1g at the distal third of the vagina every other night - estriol distal group (DEG), gel group (GG) using water-based during intercourse.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy
NCT02967510
Vaginal Atrophy
COMPLETED
PHASE2
Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women
NCT06308614
Sexual Dysfunction, Physiological
COMPLETED
PHASE2
Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days
NCT03363997
Menopause
COMPLETED
PHASE1
Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.
NCT04574999
Vaginal Atrophy
COMPLETED
PHASE3
Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms
NCT00391417
Hot Flashes
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Introduction The daily application of estrogen in the vagina can improve the hydrogen potential (pH), vaginal dryness, burning sensation, dyspareunia, and urinary symptoms. Dyspareunia is highly prevalent after menopause as well as in women after gynecological and breast cancer treatment. However, prescription of topical estrogen therapy (THT) to these women is still controversial, and they are allowed to use only moisturizing cream and vaginal lubricants.
Studies have shown increased serum concentrations of estrogens (estradiol and estrone) after intravaginal suppository containing estradiol use. However, a cohort of 13,479 women treated for breast cancer, 271 received topical hormone therapy (THT), and no increased risk for recurrence was shown in this population.
The main blood supplement to the vagina is mainly from vessels that irrigate proximal vaginal wall, a region where possibly the drug uptake is more intense. However, one study showed that the concentration of estradiol is similarly high regardless of whether the drug was applied to the proximal or distal wall of the vagina. Nevertheless, this study has not been replicated yet.
THT promotes an improvement of coital pain when used in the proximal vagina, but a large population of women with clinical conditions such as thrombophilia and breast cancer cannot benefit from this resource. It is not known if the estriol applied in the distal vagina wall can lead to high serum levels of this hormone.
OBJECTIVES This study aims to evaluate the impact of topic estriol therapy applied in distal vagina wall in coital pain, sexual function, and mood after estriol use. To evaluate serum level of this hormone after estriol use.
METHODS Study design This is a prospective, blind, and randomized clinical trial including post-menopausal women complaining of pain during intercourse. The selected women will be randomized into three groups: estriol proximal group (PEG), estriol distal group (DEG), and gel group (GG). Participants and the assistance staff will not be blinded to the intervention.
Sample Size The sample size was based on the estimated Cohen effect size. Assuming an effect size measure of 0.7 (considered large by Cohen) between groups, and considering a power test of 90% and a significance level of 5%, at least 44 subjects in each arm are required for a total of 132 participants.
Randomization Randomization will be conducted in blocks of random sizes to generate the random allocation sequence. Participants will be randomized in 23 blocks and distributed in intervention groups according to their position in each block.
Participants Sexually-active post-menopausal women between 40 to 65 years old complaining of coital pain will be invited to participate in this study. Sexual activity must include penis-vagina penetration.
Hormonal profile evaluation Blood samples will be collected before the intervention to measure basal serum levels of fasting glucose, thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH) and serum estriol. These parameters will be applied in the 12th week of intervention. The measurements of FSH, TSH, and estriol will be performed by chemiluminescence with IMMULITE® 2000 device (DPC IMMULITE® 2000 (Diagnostic Products Corporation, Los Angeles, California, United States of America (USA)). For the measurement of estriol free will be used IMMULITE® kit 2000 unconjugated estriol (SIEMENS, USA). The measurement of hormonal status will be held before the intervention (time 1) and at the end of the intervention (12 weeks). Glucose will be determined by automated spectrophotometry using the liquid enzymatic glycemia kit (Wiener Laboratory, 2000, Rosario, Argentina) Sexual function Sexual function will be evaluated with the Female Sexual Function Index (FSFI). It has 19 questions, with 6 subscales that assess desire, arousal, lubrication, orgasm, satisfaction, and pain. Each question is multiple choice and scored from 0 or 1 to 5. For calculation of the total score (range: 2 to 36), the score of each subscale was multiplied by a factor, and the 6 scores were summed. A lower score corresponds to a worse sexual function, and a score below 26.55 indicates sexual dysfunction.
Emotional condition The Hospital Anxiety and Depression Scale (HAD) was used to assess mood. This scale has 14 items and two subscales, with 7 questions regarding anxiety (HAD-A) and 7 regarding depression (HAD-D). There are four responses to each question (score of 0 to 3), and the sum of scores of each subscale provides a total score from 0 to 21. A cut-off score ≥ 9 for anxiety and depression characterizes the mental state of the woman.
All questionnaires will be applied individually by a gynecologist before the intervention (time 1) and at the end of the intervention (12 weeks) when women attend to collect blood samples. Before applying the questionnaires, women will be informed about the content and objectives of the research, and will also be informed about the issue of confidentiality.
Coital pain evaluation Coital pain will be assessed by the Analogic Visual Scale and the McGill Pain Questionnaire, a multi-dimensional tool that consists of 4 groups of constructs divided into 20 subgroups: Sensory-discriminative group (subgroups 1 to 10) relates to traction, heat, twist, among others; the motivational-affective group (subgroups 11 to 15) describes the affective dimension aspects of tension, as well as fear punishment, and neurovegetative responses; the descriptors of the cognitive component evaluation (subgroup 16) allows the patient to express the overall assessment of the painful experience; subgroups 17-20 comprise miscellaneous items. The subject can choose only one alternative for each subgroup, so the greater the number of most marked pain intensity descriptors, wherein the maximum score is 78. This questionnaire will be applied individually by a gynecologist at the beginning and at 12 weeks of intervention.
INTERVENTION For the PEG group, women will receive professional guidance to use an applicator only 3 cm inside the vagina, once at night, each other night, while lying down to sleep, with a woman in the dorsal position inserting the applicator 3 cm through the vaginal introitus. For the DEG group, women will receive professional guidance to use an applicator totally inside the vagina. The application will be recommended once each other night, while lying down to sleep, with a woman in the dorsal position inserting the applicator 10 cm through the vaginal introitus. Lubricant will be acquired by the researcher in commercial form and should be used during sexual intercourse in the vagina introitus prior to penetration of the penis.
Certification of correct use of prescription A researcher will contact the patient by telephone every two weeks to certify the proper use or any adverse symptoms related to the use of medication.
ETHICAL ASPECTS This project was approved by the Institutional Ethics Committee in Research, and all women shall sign the Informed Consent. This project will be guided according to the ethical standards by Resolution 196/96 of the National Health Council on research with the human being.
Statistical analysis Qualitative variables are described considering the absolute and relative frequencies, as quantitative variables are expressed by central position and dispersion measurements. The comparison between the study groups will be performed using the linear regression model of mixed effects; the model residue analysis will be representing through normal graphics. Cohen measure will be used as the size measure, which is expressed by the difference between the mean divided by the standard deviation. The Statistical Analysis System (SAS) will be used for data analysis.
Studies have shown increased serum concentrations of estrogens (estradiol and estrone) after intravaginal suppository containing estradiol use. However, a cohort of 13,479 women treated for breast cancer, 271 received topical hormone therapy (THT), and no increased risk for recurrence was shown in this population.
The main blood supplement to the vagina is mainly from vessels that irrigate proximal vaginal wall, a region where possibly the drug uptake is more intense. However, one study showed that the concentration of estradiol is similarly high regardless of whether the drug was applied to the proximal or distal wall of the vagina. Nevertheless, this study has not been replicated yet.
THT promotes an improvement of coital pain when used in the proximal vagina, but a large population of women with clinical conditions such as thrombophilia and breast cancer cannot benefit from this resource. It is not known if the estriol applied in the distal vagina wall can lead to high serum levels of this hormone.
OBJECTIVES This study aims to evaluate the impact of topic estriol therapy applied in distal vagina wall in coital pain, sexual function, and mood after estriol use. To evaluate serum level of this hormone after estriol use.
METHODS Study design This is a prospective, blind, and randomized clinical trial including post-menopausal women complaining of pain during intercourse. The selected women will be randomized into three groups: estriol proximal group (PEG), estriol distal group (DEG), and gel group (GG). Participants and the assistance staff will not be blinded to the intervention.
Sample Size The sample size was based on the estimated Cohen effect size. Assuming an effect size measure of 0.7 (considered large by Cohen) between groups, and considering a power test of 90% and a significance level of 5%, at least 44 subjects in each arm are required for a total of 132 participants.
Randomization Randomization will be conducted in blocks of random sizes to generate the random allocation sequence. Participants will be randomized in 23 blocks and distributed in intervention groups according to their position in each block.
Participants Sexually-active post-menopausal women between 40 to 65 years old complaining of coital pain will be invited to participate in this study. Sexual activity must include penis-vagina penetration.
Hormonal profile evaluation Blood samples will be collected before the intervention to measure basal serum levels of fasting glucose, thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH) and serum estriol. These parameters will be applied in the 12th week of intervention. The measurements of FSH, TSH, and estriol will be performed by chemiluminescence with IMMULITE® 2000 device (DPC IMMULITE® 2000 (Diagnostic Products Corporation, Los Angeles, California, United States of America (USA)). For the measurement of estriol free will be used IMMULITE® kit 2000 unconjugated estriol (SIEMENS, USA). The measurement of hormonal status will be held before the intervention (time 1) and at the end of the intervention (12 weeks). Glucose will be determined by automated spectrophotometry using the liquid enzymatic glycemia kit (Wiener Laboratory, 2000, Rosario, Argentina) Sexual function Sexual function will be evaluated with the Female Sexual Function Index (FSFI). It has 19 questions, with 6 subscales that assess desire, arousal, lubrication, orgasm, satisfaction, and pain. Each question is multiple choice and scored from 0 or 1 to 5. For calculation of the total score (range: 2 to 36), the score of each subscale was multiplied by a factor, and the 6 scores were summed. A lower score corresponds to a worse sexual function, and a score below 26.55 indicates sexual dysfunction.
Emotional condition The Hospital Anxiety and Depression Scale (HAD) was used to assess mood. This scale has 14 items and two subscales, with 7 questions regarding anxiety (HAD-A) and 7 regarding depression (HAD-D). There are four responses to each question (score of 0 to 3), and the sum of scores of each subscale provides a total score from 0 to 21. A cut-off score ≥ 9 for anxiety and depression characterizes the mental state of the woman.
All questionnaires will be applied individually by a gynecologist before the intervention (time 1) and at the end of the intervention (12 weeks) when women attend to collect blood samples. Before applying the questionnaires, women will be informed about the content and objectives of the research, and will also be informed about the issue of confidentiality.
Coital pain evaluation Coital pain will be assessed by the Analogic Visual Scale and the McGill Pain Questionnaire, a multi-dimensional tool that consists of 4 groups of constructs divided into 20 subgroups: Sensory-discriminative group (subgroups 1 to 10) relates to traction, heat, twist, among others; the motivational-affective group (subgroups 11 to 15) describes the affective dimension aspects of tension, as well as fear punishment, and neurovegetative responses; the descriptors of the cognitive component evaluation (subgroup 16) allows the patient to express the overall assessment of the painful experience; subgroups 17-20 comprise miscellaneous items. The subject can choose only one alternative for each subgroup, so the greater the number of most marked pain intensity descriptors, wherein the maximum score is 78. This questionnaire will be applied individually by a gynecologist at the beginning and at 12 weeks of intervention.
INTERVENTION For the PEG group, women will receive professional guidance to use an applicator only 3 cm inside the vagina, once at night, each other night, while lying down to sleep, with a woman in the dorsal position inserting the applicator 3 cm through the vaginal introitus. For the DEG group, women will receive professional guidance to use an applicator totally inside the vagina. The application will be recommended once each other night, while lying down to sleep, with a woman in the dorsal position inserting the applicator 10 cm through the vaginal introitus. Lubricant will be acquired by the researcher in commercial form and should be used during sexual intercourse in the vagina introitus prior to penetration of the penis.
Certification of correct use of prescription A researcher will contact the patient by telephone every two weeks to certify the proper use or any adverse symptoms related to the use of medication.
ETHICAL ASPECTS This project was approved by the Institutional Ethics Committee in Research, and all women shall sign the Informed Consent. This project will be guided according to the ethical standards by Resolution 196/96 of the National Health Council on research with the human being.
Statistical analysis Qualitative variables are described considering the absolute and relative frequencies, as quantitative variables are expressed by central position and dispersion measurements. The comparison between the study groups will be performed using the linear regression model of mixed effects; the model residue analysis will be representing through normal graphics. Cohen measure will be used as the size measure, which is expressed by the difference between the mean divided by the standard deviation. The Statistical Analysis System (SAS) will be used for data analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Dyspareunia
Menopause
Sexual Dysfunction
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
we compared three groups: women using estriol in the proximal vagina wall, women using estriol in the distal vagina wall, and women using gel lubricant
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
proximal estriol group (PEG )
This arm is composed of women using estriol 1 mg / 1g in the proximal third of vagina every other night
Group Type
ACTIVE_COMPARATOR
Estriol
Intervention Type
DRUG
Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
distal estriol group (DEG)
This arm is composed of women using estriol 1 mg / 1g in the distal third of the vagina every other night
Group Type
EXPERIMENTAL
Distal estriol
Intervention Type
DRUG
Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
Control group (CG)
This arm is composed of women using vaginal gel lubricant base water during intercourse
Group Type
PLACEBO_COMPARATOR
Vaginal Gel
Intervention Type
DRUG
Women using a base water gel lubricant during intercourse
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Estriol
Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
Intervention Type
DRUG
Distal estriol
Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
Intervention Type
DRUG
Vaginal Gel
Women using a base water gel lubricant during intercourse
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
PEG
DEG
CG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women with a clinical diagnosis of menopause
* FSH\> 40 milli-International unit (mIU/ml)
* Having sex including penetration of penis into vagina
* Pain during penetration
* Active sexual partners
* Stable relationship.
* FSH\> 40 milli-International unit (mIU/ml)
* Having sex including penetration of penis into vagina
* Pain during penetration
* Active sexual partners
* Stable relationship.
Exclusion Criteria
* Previous use of steroids in genital area in the last month
* Thromboembolism history
* Renal insufficiency
* Cholestatic jaundice
* Degenerative vulvar pathology
* Breast cancer
* Endometrial cancer
* Vulvar cancer
* Vaginal cancer history
* Prior radiotherapy to the genital region
* Smoking
* Acute urogenital infections
* Vulvovaginitis
* Urinary tract infection
* Genital herpes
* Genital prolapse grades II, III and IV by Baden Walker
* Systemic hormonal therapy in the last three months
* Use of antidepressants drugs
* Diabetes
* Thyroid disorder
* Cognitive restrictions
* Thromboembolism history
* Renal insufficiency
* Cholestatic jaundice
* Degenerative vulvar pathology
* Breast cancer
* Endometrial cancer
* Vulvar cancer
* Vaginal cancer history
* Prior radiotherapy to the genital region
* Smoking
* Acute urogenital infections
* Vulvovaginitis
* Urinary tract infection
* Genital herpes
* Genital prolapse grades II, III and IV by Baden Walker
* Systemic hormonal therapy in the last three months
* Use of antidepressants drugs
* Diabetes
* Thyroid disorder
* Cognitive restrictions
Minimum Eligible Age
40 Years
Maximum Eligible Age
65 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sao Paulo
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lucia Alves da Silva Lara
M.D, Ph.D. Gynecology & Obstetrics, Sexual Health.
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
lucia a Silva Lara, PhD
Role: PRINCIPAL_INVESTIGATOR
Faculdade de Medicina de Ribeirão Preto - Universidade de Sao Paulo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital das Clínicas de Ribeirão Preto
Ribeirão Preto, São Paulo, Brazil
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Brazil
References
Explore related publications, articles, or registry entries linked to this study.
Lovejoy TI, Turk DC, Morasco BJ. Evaluation of the psychometric properties of the revised short-form McGill Pain Questionnaire. J Pain. 2012 Dec;13(12):1250-7. doi: 10.1016/j.jpain.2012.09.011.
Reference Type
BACKGROUND
Varoli FK, Pedrazzi V. Adapted version of the McGill Pain Questionnaire to Brazilian Portuguese. Braz Dent J. 2006;17(4):328-35. doi: 10.1590/s0103-64402006000400012.
Reference Type
RESULT
Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, Kirkegard Y, Fraser IS. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005 Mar;8(1):83-92. doi: 10.1080/13697130500087016.
Reference Type
RESULT
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
Reference Type
RESULT
Resplande J, Gholami SS, Graziottin TM, Rogers R, Lin CS, Leng W, Lue TF. Long-term effect of ovariectomy and simulated birth trauma on the lower urinary tract of female rats. J Urol. 2002 Jul;168(1):323-30.
Reference Type
RESULT
Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208. doi: 10.1080/009262300278597.
Reference Type
RESULT
Simon JA, Maamari RV. Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy. Climacteric. 2013 Aug;16 Suppl 1:37-43. doi: 10.3109/13697137.2013.807606.
Reference Type
RESULT
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2003;(4):CD001500. doi: 10.1002/14651858.CD001500.
Reference Type
RESULT
Ting AY, Blacklock AD, Smith PG. Estrogen regulates vaginal sensory and autonomic nerve density in the rat. Biol Reprod. 2004 Oct;71(4):1397-404. doi: 10.1095/biolreprod.104.030023. Epub 2004 Jun 9.
Reference Type
RESULT
Lara LA, Useche B, Ferriani RA, Reis RM, de Sa MF, de Freitas MM, Rosa e Silva JC, Rosa e Silva AC. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. J Sex Med. 2009 Jan;6(1):30-9. doi: 10.1111/j.1743-6109.2008.01052.x.
Reference Type
RESULT
Lara LA, Cartagena-Ramos D, Figueiredo JB, Rosa-E-Silva ACJ, Ferriani RA, Martins WP, Fuentealba-Torres M. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2023 Aug 24;8(8):CD009672. doi: 10.1002/14651858.CD009672.pub3.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
62443916.5.0000.5440
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
NCT02253173
COMPLETED
PHASE3
Treating Postmenopausal Dyspareunia Where it Hurts
NCT03240081
COMPLETED
PHASE4
Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction
NCT03018106
TERMINATED
PHASE4
Effect of Estradiol Topical Products
NCT05645393
COMPLETED
EARLY_PHASE1
Effect of Local Estriol Treatment Before Vaginal Repair Surgery
NCT06391372
ACTIVE_NOT_RECRUITING
PHASE3
Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients
NCT03032848
COMPLETED
PHASE4
The Vaginal Health Trial
NCT02516202
COMPLETED
PHASE3
A Study Evaluating the Effects of Topical Clitoral Estradiol Cream in Post Menopausal Women
NCT02859285
COMPLETED
NA
A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis
NCT00816556
TERMINATED
PHASE3
Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women
NCT01816139
COMPLETED
PHASE3
Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream
NCT04232813
COMPLETED
PHASE3
Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women
NCT02224313
COMPLETED
PHASE3
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
NCT00613002
COMPLETED
PHASE3
Preference of Women With Recurrent Urinary Tract Infection for Vaginal Estradiol Tablet vs Cream
NCT05723601
ACTIVE_NOT_RECRUITING
PHASE4
Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women
NCT00560924
TERMINATED
PHASE3
Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer
NCT00002976
TERMINATED
PHASE3
Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women
NCT01400776
COMPLETED
PHASE3
Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients
NCT00698035
COMPLETED
PHASE2
Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers
NCT00467493
COMPLETED
PHASE2
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
NCT01845649
COMPLETED
PHASE3
Sexual Effects of Transdermal or Vaginal Testosterone
NCT06794346
ACTIVE_NOT_RECRUITING
PHASE2
Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women.
NCT03556800
UNKNOWN
PHASE1
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
NCT00331123
COMPLETED
PHASE3